5 April 2012
Changes in the European QP Association Board
So far, the European QP Association
has been led by four industry representatives and two authority
representatives. Now the Board has decided on some extensions on
both sides and therefore nominated two new members: Dr Ulrich Kissel
from Roche in Germany will strengthen the industry side of the Board
as a nominated member, Edit Szőcs from the Hungarian National
Institute of Pharmacy (NIP) will bring in her expertise from an
authority’s perspective.
Dr Kissel, a German pharmacist, has more than 15 years of experience
in the industry and covered a variety of roles in quality control
and quality assurance as well as strategic logistics and product and
technology strategy in manufacturing. Edit Szőcs, a GMP Inspector at
NIP with over 10 years of QA experience in the pharmaceutical
industry, gained her expertise in manufacturing, testing and
packaging of various pharmaceutical dosage forms in Canada.
Further changes refer to QP Association’s Working Group
“Investigational Medicinal Products”. The group has been part of the
European QP Association for a couple of years already, and many of
you also know its workshops at the annual QP Forums.
Now Dr Annemiek Stijnen and Martine Tratsaert, who initiated the
Working Group and have been leading it since its foundation, will be
joined by Dr Susanne Ding from Boehringer Ingelheim Pharma, Germany,
and Philippe Van der Hofstadt from B&C Group in Belgium.
Some of you may already know Dr Ding from previous IMP workshops. As
Qualified Person for IMPs at Boehringer Ingelheim Pharma she has
been in charge of releasing clinic samples for the use in clinical
studies worldwide since 2005. Philippe Van der Hofstadt started B&C
Group in 1999. Today, he is CEO of the European niche packaging &
logistics company dedicated to clinical research that is now active
on a global scale.
|
